← Leaderboards
Matthew Collins
Emory University
$2,679,353
Attributed
$5,381,662
Total exposure
5
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.7M · FY2018–25$5M$3.8M$2.5M$1.3M$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,381,662 · 5
By mechanism
R01$3,776,002 · 2
U01$877,587 · 1
R21$458,500 · 1
K22$269,573 · 1
Top collaborators
- Srilatha Edupuganti2 shared
- Christopher D Heaney2 shared
- David Richard Myers2 shared
- Mauro M Teixeira2 shared
Most similar at Emory University
Same institution · by research overlap
- Arash Grakoui$19,890,946
- E. John Wherry$31,162,830
- Naglaa H. Shoukry$2,568,124
- Jesse Waggoner$1,668,785
- Manoj Thapa$618,461
Others in their field
Other Emerging Leaders on “Infection”
- Chanza Baytop · Westat, Inc.$271,217,917
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$207,651,224
- Kimberly Smith · Ppd Development Lp$115,671,664
- Kevin Urdahl · Seattle Children'S Hospital$85,664,942
- Yunda Huang · Fred Hutchinson Cancer Center$73,602,469
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,912,072
Research focus
InfectionCollectionInnovationCross ReactivityDetectionAntibody ResponseResponseFutureImmunityAntigensVaccinesMonitorAreaImmune ResponsePublic HealthDengueSamplingAntibodiesDiagnosticDiagnosisPreventMolecularPhenotypeProtocols Documentation
Grant awards (8)
Form with function: Rapid phenotypic carbapenemase testing to improve detection of carbapenemase-producing organisms$3,055,197
R01 · FY2025 · AI
Integrating low-cost and versatile technologies to achieve colorimetric HCV and HIV detection from whole blood$720,805
R01 · FY2025 · AI
A Phase 2b randomized open label trial to assess the quality and balance of dengue immunity elicited by prime-boost combinations of TAK-003 and Butantan-DV$578,157
U01 · FY2025 · AI · contact PI
A Phase 2b randomized open label trial to assess the quality and balance of dengue immunity elicited by prime-boost combinations of TAK-003 and Butantan-DV$299,430
U01 · FY2025 · AI · contact PI
Multiplex oral fluid antibody assay for arbovirus diagnosis, surveillance and prevention$120,874
R21 · FY2019 · AI
Seroepidemiologic risk for congenital Zika syndrome and adaptive immunity of fetal infection$107,576
K22 · FY2019 · AI · contact PI
Multiplex oral fluid antibody assay for arbovirus diagnosis, surveillance and prevention$337,626
R21 · FY2018 · AI
Seroepidemiologic risk for congenital Zika syndrome and adaptive immunity of fetal infection$161,997
K22 · FY2018 · AI · contact PI